Loading...
•
Dec 31, 2024
Merck Q4 2024 Earnings Report
Key Takeaways
Merck reported a 7% increase in fourth-quarter 2024 sales, reaching $15.6 billion, driven by strong performance in oncology and animal health segments. However, challenges in the vaccine segment, particularly with Gardasil in China, impacted overall results.
Forward Guidance
Merck projects 2025 revenue between $64.1 billion and $65.6 billion, with adjusted EPS ranging from $8.88 to $9.03, both below analyst expectations.
Positive Outlook
- Strong performance of Keytruda with 19% sales growth.
- Animal Health segment showed resilience with 4% growth.
- Advancements in late-stage pipeline, including new drug approvals.
- Strategic focus on oncology and animal health for future growth.
- Commitment to addressing dependency on Keytruda through diversification.
Challenges Ahead
- Pause in Gardasil shipments to China due to weak demand.
- Withdrawal of $11 billion sales target for Gardasil by 2030.
- 2025 revenue and EPS guidance below analyst expectations.
- Stock experienced significant decline following earnings report.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...